Organon & Co. (OGN) Cash on Hand per Share

Corporate company logo of organon.com (OGN)

Organon & Co. management has successfully stabilized the corporate structure following the business spin-off. The cash per share trend reflects current liquidity, while 5.54 marks a new level. Growth potential is driven by developments in reproductive medicine and hormones, alongside resilience provided by a diversified contraceptive portfolio in a stable market.

Organon & Co - OGN Cash per Single Share (period 07/04/2022 - 11/20/2026)

Analytical breakdowns for Organon (OGN)

- current price and projected stock value:
- cash and cash flow metrics:
Summary company analysis:OGN Organon Pharma
Finished products of organon.com

This indicator reflects net liquidity per share minus all liabilities, allowing for an assessment of the company's actual financial reserve. By analyzing changes in the cash position per share, a conservative investor can determine the ability of Organon & Co. (OGN) to service significant debt and mitigate the risks of patent expiration, which is critical for long-term business sustainability amid pricing pressure.